Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 24, 2015 0:13:27 GMT -5
Not only is Alfred Mann a brilliant scientist, but he is also a wise investor. Alfred has put more than a $billion into Afrezza; if MannKind needs an additional $100 million to get through this transition period, do you believe he will not add an additional 10% to see a return on his initial investment?
|
|
|
|
Post by benyiju on Nov 24, 2015 0:39:43 GMT -5
Kastanes, you are the consumate True Believer! I hope you're right, certainly his taking over the CEO role again suggests he's not going to let MNKD go down without a fight. Unfortunately, for obvious reasons a nonagenarian is not a long-term solution for MNKD's fiscal health. So unless he's prepared to immediately set up an endowment for MNKD, we need what we've always needed: scripts and cash.
|
|
|
|
Post by rrtzmd on Nov 24, 2015 1:03:21 GMT -5
Not only is Alfred Mann a brilliant scientist, but he is also a wise investor. Alfred has put more than a $billion into Afrezza; if MannKind needs an additional $100 million to get through this transition period, do you believe he will not add an additional 10% to see a return on his initial investment? Where was Mr. Mann back in August? Why did MNKD have to resort to the almost embarrassing "back door" of cross listing in Israel in order to use TASE rules to force ETFs to buy MNKD stock? For that matter, where is Sanofi? Sanofi is supposed to be a partner, right? They're responsible for marketing the drug and have an economic interest in MNKD's survival and success, so why haven't they pitched in? |
|
|
|
Post by benyiju on Nov 24, 2015 1:14:01 GMT -5
The problem is that Sanofi may have an interest in MNKD's weakness, or at least see themselves as potentially able to profit from it. And, as we've seen, Sanofi has a very chequered past when it comes to dealings with 'partners'. Furthermore, in this case it is an unequal partnership in which Sanofi holds most of the cards.
|
|
|
|
Post by jpg on Nov 24, 2015 1:42:02 GMT -5
Does Mann even have the financial means to inject 100 million? If he did he should have done that instead of this TASE thing.
|
|
|
|
Post by peppy on Nov 24, 2015 3:14:00 GMT -5
Not only is Alfred Mann a brilliant scientist, but he is also a wise investor. Alfred has put more than a $billion into Afrezza; if MannKind needs an additional $100 million to get through this transition period, do you believe he will not add an additional 10% to see a return on his initial investment? GREAT..... another bankruptcy is not an option thread...... a test in psychology.... do negative threads draw more hits? ? it is true! the problem solving thread, no hits.... the bankruptcy thread,,,, hit after hit!!!! WTG. hmmm, negative after negative thread.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 24, 2015 7:48:25 GMT -5
Kastanes, you are the consumate True Believer! I hope you're right, certainly his taking over the CEO role again suggests he's not going to let MNKD go down without a fight. Unfortunately, for obvious reasons a nonagenarian is not a long-term solution for MNKD's fiscal health. So unless he's prepared to immediately set up an endowment for MNKD, we need what we've always needed: scripts and cash. How can one not believe Afrezza will become one of the greatest selling medications in history? With additional products being developed, I see tremendous long term growth in MannKind. My point for creating the thread was directed at "investors"; to believe Alfred would not add an additional 10% in order to save his original investment is ludicrous. I will be holding on. Some will call me foolish, but I don't see a better investment opportunity than MannKind. |
|
|
|
Post by dictatorsaurus on Nov 24, 2015 8:15:35 GMT -5
I think us longs are sick and tired of "believing" and ready to see results. We are riding on hope and nothing else. The fact that we have multiple threads and speculations regarding EU filling tells how chaotic and non-transparent the situation is. So far neither Mannkind nor Sanofi have disclosed how they plan on turning things around. The waiting game feels more like the losing game.
/End of pessimistic post.
|
|
|
|
Post by purge on Nov 24, 2015 8:28:55 GMT -5
Management has let us down time and time again. We have no clue what is going on. I have said it before and I will say it again. Management at Mannnkind act like they hate longs. They have given us nothing buy hope. Hope is a poor poor reason for holding an investment.
We have no clue what is going on and when was the last time management gave us any real information that we all seek? That says it all.
|
|
|
|
Post by sportsrancho on Nov 24, 2015 9:31:48 GMT -5
Not only is Alfred Mann a brilliant scientist, but he is also a wise investor. Alfred has put more than a $billion into Afrezza; if MannKind needs an additional $100 million to get through this transition period, do you believe he will not add an additional 10% to see a return on his initial investment? Sentiment, and peoples bank accounts are causing the pps to go lower. You look at things differently when you are losing money if only on paper. Tax selling also. When you sell sometimes you hope to be proven right. So things get more and more negative and more sell. When things turn around people will be saying they knew Al wouldn't let us or diabetic's down! Logical kastanes! To me it's a no-brainer:-) |
|
|
|
Post by silentknight on Nov 24, 2015 9:58:29 GMT -5
I think us longs are sick and tired of "believing" and ready to see results. We are riding on hope and nothing else. The fact that we have multiple threads and speculations regarding EU filling tells how chaotic and non-transparent the situation is. So far neither Mannkind nor Sanofi have disclosed how they plan on turning things around. The waiting game feels more like the losing game. /End of pessimistic post. At some point hope has to give way to results. What you are seeing from the market is the loss of the former due to absence of the latter. Bankruptcy might not be an option for a year or so, given the small amount of capital generated from the TASE sell and the available funds through the Mann Group, but then what? Al isn't getting any younger and as a man in his ninety's, his mortality is something that the company and he himself should be factoring in regarding his stewardship of his namesake. When he passes, his trustees might not be as amenable to providing more funding for a struggling biotech company who hasn't shown results. Al could have stepped up and loaned more money instead of turning to TASE but he didn't. Perhaps it shows his tolerance for propping the company up is drawing to a close. Perhaps it doesn't. While bankruptcy in the short-term might not be an option, in the long-term it is. Any company with the capital concerns and lack of revenue that MNKD has faces that danger. Our hope and belief in Al and the product shouldn't cloud our objectivity to where the company is. I take the fact that he is the interim CEO to be a good thing. It means that he is still invested personally in the company and I'm optimistic that it may be the start of a turn around, beginning with the hiring of a strong CEO that knows how to navigate rough waters. Hell, when Al finally leaves this world behind, he might endow the company with a hefty sum to ensure it thrives long after he's gone. We'd need that strong CEO at the helm to do that. I'm hoping the BOD finds him/her soon. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 24, 2015 10:27:39 GMT -5
I think us longs are sick and tired of "believing" and ready to see results. We are riding on hope and nothing else. The fact that we have multiple threads and speculations regarding EU filling tells how chaotic and non-transparent the situation is. So far neither Mannkind nor Sanofi have disclosed how they plan on turning things around. The waiting game feels more like the losing game. /End of pessimistic post. At some point hope has to give way to results. What you are seeing from the market is the loss of the former due to absence of the latter. Bankruptcy might not be an option for a year or so, given the small amount of capital generated from the TASE sell and the available funds through the Mann Group, but then what? Al isn't getting any younger and as a man in his ninety's, his mortality is something that the company and he himself should be factoring in regarding his stewardship of his namesake. When he passes, his trustees might not be as amenable to providing more funding for a struggling biotech company who hasn't shown results. Al could have stepped up and loaned more money instead of turning to TASE but he didn't. Perhaps it shows his tolerance for propping the company up is drawing to a close. Perhaps it doesn't. While bankruptcy in the short-term might not be an option, in the long-term it is. Any company with the capital concerns and lack of revenue that MNKD has faces that danger. Our hope and belief in Al and the product shouldn't cloud our objectivity to where the company is. I take the fact that he is the interim CEO to be a good thing. It means that he is still invested personally in the company and I'm optimistic that it may be the start of a turn around, beginning with the hiring of a strong CEO that knows how to navigate rough waters. Hell, when Al finally leaves this world behind, he might endow the company with a hefty sum to ensure it thrives long after he's gone. We'd need that strong CEO at the helm to do that. I'm hoping the BOD finds him/her soon. The TASE thing means that for now, Al does not have to pull more money out of his pocket. If Al had reached into his pocket now, then passed away at some point down the road, doing the TASE thing after Al passed would have been a much more difficult task. By doing TASE sooner rather than later, Al has the option in the future of investing more of his money into Mannkind (posthumous via a legal directive to his estate if need be). At this years annual shareholder meeting, Matt said (while seated directly next to Al) that The Mann Group would providing funding to Mannkind above and beyond the $30 in existing funds that The Mann Group has set aside for Mannkind if need be. Cash is my biggest concern though and Kastanes, I appreciate your optimism but per Matt, the company burns $8 - $10mm / month. I don't know how much we have in the bank at this point, how much above the $30mm Al is willing to put into Mannkind via The Mann Group. Not sure how many shares are issued but not outstanding that can be sold for additional cash. If no TS deal in the next few months and Rx count remains slow with no new country commercializing Afrezza, we continue to deplete cash. Hakans departure will require some additional $$, bringing on a new CEO will require additional $$ and we are on the hook with Amphastar, see bottom of p 19 ir.amphastar.com/secfiling.cfm?filingid=1171843-14-5537&cik=. If nothing changes in 6 months, cash on hand needs additional replenishment then share price only gets driven lower. At what PPS does issuing more shares no longer become a realistic option not to mention going concern issues. Without significant growth in Afrezza over the next 3-4 months, the only white knight that shows up is one that takes a big chunk of Mannkind equity or highly dilutive warrants for the loan and if this is the route that is taken, no way it makes sense to mess around with a $50mm or even $100mm raise. It would need to be a one shot deal that gives the company more than ample $$ to run 3-4 years. With the above being said, maybe Al has a rabbit or two he can pull out of his hat. No way he has come this far without overcoming some hills that are way bigger than Everest. Still blows me away that a product like Afrezza, which is so far superior to the RAAs and oral meds cannot be growing at a faster rate. Hell, Sam's endo has one of the largest endocrinology practices in the country. If Sanofi just had the top 50 - 100 endos writing Afrezza Rx could would be miles ahead of where it is now. Not selling a share but not very comfortable with where we are now. |
|
|
|
Post by jurystillout on Nov 24, 2015 10:44:17 GMT -5
Not only is Alfred Mann a brilliant scientist, but he is also a wise investor. Alfred has put more than a $billion into Afrezza; if MannKind needs an additional $100 million to get through this transition period, do you believe he will not add an additional 10% to see a return on his initial investment? If we get to that point, I sure hope your right however only Al Mann knows what he'll do and for what reason he'll do it. I sure don't feel comfortable risking my investments on what I think someone might or might not do, in my opinion that's called gambling not investing. I'm sticking around with the assumption that we won't get to the point of finding out what Al will do. I do believe that his current liability in the company is a huge incentive for him to turn this ship in the right direction and for right now, I'm glad to see him in charge. |
|
|
|
Post by pengiep on Nov 24, 2015 10:47:38 GMT -5
AL went to the TASE because of Rule # 1 of investing, if you can, use other peoples money.
|
|
|
|
Post by dreamboatcruise on Nov 24, 2015 10:57:51 GMT -5
Not only is Alfred Mann a brilliant scientist, but he is also a wise investor. Alfred has put more than a $billion into Afrezza; if MannKind needs an additional $100 million to get through this transition period, do you believe he will not add an additional 10% to see a return on his initial investment? If he is a wise investor would he not prefer waiting until share price is much lower to get the most for his money? Obviously he is not motivated to jump in early merely to stabilize share price or he would have done it long ago. They could have announced a secondary with Al committing to take $50M and done the deal at a price much higher than where we are today. I too believe Al would not let the company lapse into bankruptcy and lose control of Afrezza. I don't think that belief would make this a good investment at this point. That belief would make it a good investment to wait for however low it drops and jump in WHEN Al decides to put more money into it... assuming he doesn't protect his investment by taking the company private. You seem to assume that Al protecting his investment is going to protect yours. Maybe he lends the company money and there is no dilution as robsacher has suggested. However, I certainly don't know how one could have much confidence in Al being a savior for current shareholders, even if he can assumed to be motivated to save Afrezza. |
|
? it is true!
